BeyondSpring Inc. (BYSI)
- Previous Close
2.4700 - Open
2.4700 - Bid --
- Ask 2.5900 x 100
- Day's Range
2.4113 - 2.6400 - 52 Week Range
0.6530 - 4.0000 - Volume
20,814 - Avg. Volume
218,534 - Market Cap (intraday)
100.695M - Beta (5Y Monthly) 0.32
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5400 - Earnings Date May 14, 2024 - May 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.25
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
beyondspringpharma.comRecent News: BYSI
Performance Overview: BYSI
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BYSI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BYSI
Valuation Measures
Market Cap
100.70M
Enterprise Value
96.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
57.46
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.69%
Return on Equity (ttm)
--
Revenue (ttm)
1.55M
Net Income Avi to Common (ttm)
-27.51M
Diluted EPS (ttm)
-0.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
15.39M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Research Analysis: BYSI
Company Insights: BYSI
BYSI does not have Company Insights